276 related articles for article (PubMed ID: 12888882)
1. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
Favot L; Keravis T; Holl V; Le Bec A; Lugnier C
Thromb Haemost; 2003 Aug; 90(2):334-43. PubMed ID: 12888882
[TBL] [Abstract][Full Text] [Related]
2. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4.
Favot L; Keravis T; Lugnier C
Thromb Haemost; 2004 Sep; 92(3):634-45. PubMed ID: 15351862
[TBL] [Abstract][Full Text] [Related]
3. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
5. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
6. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes.
Keravis T; Komas N; Lugnier C
J Vasc Res; 2000; 37(4):235-49. PubMed ID: 10965223
[TBL] [Abstract][Full Text] [Related]
12. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
Haynes J; Killilea DW; Peterson PD; Thompson WJ
J Pharmacol Exp Ther; 1996 Feb; 276(2):752-7. PubMed ID: 8632346
[TBL] [Abstract][Full Text] [Related]
13. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes.
Rivet-Bastide M; Vandecasteele G; Hatem S; Verde I; Bénardeau A; Mercadier JJ; Fischmeister R
J Clin Invest; 1997 Jun; 99(11):2710-8. PubMed ID: 9169501
[TBL] [Abstract][Full Text] [Related]
14. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.
Phillips PG; Long L; Wilkins MR; Morrell NW
Am J Physiol Lung Cell Mol Physiol; 2005 Jan; 288(1):L103-15. PubMed ID: 15377497
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
16. Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Hiramoto K; Murata T; Shimizu K; Morita H; Inui M; Manganiello VC; Tagawa T; Arai N
Cell Signal; 2014 Sep; 26(9):1807-17. PubMed ID: 24705027
[TBL] [Abstract][Full Text] [Related]
17. Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human glomerulosa cells.
Côté M; Payet MD; Rousseau E; Guillon G; Gallo-Payet N
Endocrinology; 1999 Aug; 140(8):3594-601. PubMed ID: 10433216
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
